Amarin to Present New REDUCE-IT Data and Mechanistic Research at ACC 2026
Event summary
- Amarin will present new REDUCE-IT data on patients at extreme cardiovascular risk at the ACC 2026 conference.
- Oral presentation on March 29, 2026, detailing efficacy of icosapent ethyl in high-risk patients.
- Poster presentation on March 28, 2026, exploring the effects of EPA on lipoprotein(a) oxidation.
- REDUCE-IT study followed 8,179 patients across 11 countries, with primary results published in 2018.
The big picture
Amarin's presentation at ACC 2026 underscores the ongoing effort to expand the clinical utility of VASCEPA beyond its current indications. The focus on extreme-risk patients and mechanistic insights into EPA's effects could position the drug as a key player in addressing residual cardiovascular risk. The broader industry trend of targeting high-risk patient subgroups with specialized therapies highlights the strategic importance of these findings.
What we're watching
- Clinical Validation
- How the new REDUCE-IT data will impact the perception of VASCEPA's efficacy in extreme-risk patients.
- Regulatory Strategy
- Whether the mechanistic research on EPA will support expanded indications or labeling changes.
- Market Differentiation
- The pace at which Amarin can leverage this data to strengthen its position against competitors in the cardiovascular space.
Related topics